Last updated: February 20, 2026
What is NDC 00713-0879?
NDC 00713-0879 corresponds to Vyzulta (latanoprostene bunod) ophthalmic solution, indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It was approved by the FDA on December 8, 2017, manufactured by Bausch + Lomb.
Market Context
Therapeutic Landscape
Vyzulta operates within the glaucoma treatment segment, which includes multiple classes: prostaglandin analogs, beta-blockers, alpha agonists, carbonic anhydrase inhibitors, and parasympathomimetics. The glaucoma drug market was valued at approximately $4.8 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.5% through 2027.[1]
Competitive Position
Vyzulta's differentiation lies in its dual mechanism: boosting nitric oxide and prostaglandin pathways, aiming for improved intraocular pressure (IOP) reduction over standard prostaglandins. Major competitors include:
- Latanoprost (Xalatan)
- Travoprost (Travatan Z)
- Bimatoprost (Lumigan)
- Tafluprost (Zioptan)
- Netarsudil (Rhopressa)
- Combigan (brimonidine/timolol)
Vyzulta’s share remains modest, as it competes with well-established agents. Recommended retail price (RRP) is approximately $370–$400 per 2.5 mL, with patients often using once daily.[2]
Market Drivers
- Unmet needs for more effective ocular hypotensive agents.
- Doctor and patient preference for less frequent dosing.
- Evolving formulations improving patient adherence.
- Increasing prevalence of glaucoma globally, expected to reach 112 million cases in 2040.[3]
Price Dynamics and Projections
Current Pricing and Insurance Coverage
- Wholesale Acquisition Cost (WAC): ~$360–$400 per 2.5 mL supply.
- Average net price after rebates/negotiations: approximately 10–15% lower.
- Insurance market penetration is high; copays range between $10–$50 depending on plans.
Factors Influencing Future Pricing
- Regulatory changes or formulary placements that favor Vyzulta could lead to increased utilization.
- Competition's impact on pricing—generic prostaglandin analogs are significantly cheaper.
- Distribution strategies—direct-to-consumer campaigns may allow for higher retail margins.
- Patent life and potential exclusivity extensions.
Price Projection (Next 3–5 Years)
| Year |
Estimated Average Price |
Notes |
| 2023 |
$370–$400 |
Current market prices |
| 2024 |
$355–$390 |
Slight decreases possible due to generic prostaglandins |
| 2025 |
$340–$380 |
Pricing pressure from generics, reimbursement factors |
| 2026 |
$330–$370 |
Potential stabilization or slight decline |
| 2027 |
$320–$360 |
Competition and market saturation could stabilize prices |
Market Penetration and Sales Forecast
- Projected annual sales: $100–$150 million in North America during 2023–2025.
- Growth hinges on increased formulary acceptance and prescriber adoption.
- International expansion will influence total sales volume, especially in Europe and Asia.
Risks and Opportunities
- Patent litigation or new patent protections could extend exclusivity.
- Entry of new combination therapies could erode market share.
- Cost reductions driven by manufacturing efficiencies may allow price flexibility.
Key Takeaways
- NDC 00713-0879 is a branded glaucoma treatment with moderate market penetration.
- Pricing remains relatively high but is pressured by generics and biosimilars.
- Future price trends will depend heavily on formulary inclusion, competitive dynamics, and regulatory environment.
- Strong growth prospects exist due to the rising glaucoma burden but face substantial competition.
- Strategic positioning within treatment algorithms influences revenue potential.
FAQs
Q1: How does Vyzulta’s price compare globally?
It is most expensive in the U.S., with prices often lower in Europe and emerging markets due to different pricing regulations and reimbursement systems.
Q2: What are the key regulatory considerations?
Patent protections and exclusivity extensions are vital. No recent patent challenges have significantly impacted Vyzulta, but future biosimilar or generic entries could.
Q3: How likely is price erosion from generics?
Generic prostaglandins are available at roughly 25–40% lower prices than Vyzulta, which could pressure branded pricing over time.
Q4: What is the market share outlook?
Vyzulta’s share remains limited (<5%) but could grow with increased awareness and formulary inclusion.
Q5: How can manufacturers sustain revenues?
Focus on differentiating efficacy, expanding indications, and optimizing payer negotiations to secure preferred formulary status.
References
[1] IQVIA. (2023). Global Ophthalmic Market Data.
[2] Bausch + Lomb. (2022). Vyzulta Pricing and Market Access Profile.
[3] Tham, Y.C., et al. (2014). Global prevalence of glaucoma and projections. Ophthalmology, 121(11), 2089–2096.
